Effects of quetiapine on sleep in nonpsychiatric and psychiatric conditions.
To evaluate the use of immediate-release quetiapine for the treatment of insomnia. Pre-MEDLINE and MEDLINE were searched (1966 to October 2008) using the terms quetiapine, sleep, insomnia, and antipsychotics. All studies and case reports evaluating insomnia as a primary endpoint were reviewed. The role of quetiapine for improving sleep in various patient populations is uncertain. Quetiapine has moderately sedative properties, and doses used in treatment of insomnia have ranged from 12.5 to 800 mg. Results of clinical trials and observations in case studies have revealed possible beneficial effects of quetiapine on several subjective and objective sleep parameters. In most studies, significant improvements in sleep were found in areas of total sleep time, sleep efficiency, and subjective sleep scores. However, some of these results may not be clinically significant. Also, quetiapine has been found to have adverse effects such as periodic leg movements, akathisia, and metabolic complications. Additionally, changes in rapid eye movement (REM) and percentage of REM sleep have been noted in different populations and need further study. Despite quetiapine's sedative properties, current data do not appear to support its use as first-line treatment for sleep complications. However, it may be useful for treatment of insomnia in patients with psychiatric disorders (eg, bipolar, schizophrenia) who do not respond to primary or secondary treatments. Further studies are needed to define the placement, dose, and adverse effects of quetiapine for the treatment of sleep problems.